ArticleClinical and translational medicine2025
Bispecific antibody targeting CD40 and HER2 potentiates therapeutic efficacy by reprogramming macrophages within the tumour microenvironment.
Na Li et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.